高强度聚焦超声（HIFU），被称为「隔山打牛的医学艺术」，
是中国原创、全球领先的无创治疗技术。
High-Intensity Focused Ultrasound (HIFU) — often called the medical art of striking through the mountain — is a China-originated, globally leading non-invasive therapy.
HIFU-PRO 是我们战略合作伙伴普罗医学的旗舰 HIFU 设备，
核心落地型号为 P300，已获得欧盟 CE 等多项国际认证。
HIFU-PRO is the flagship HIFU system from our strategic partner PRO Medical. The core deployed model is P300, with EU CE and other international certifications.
先建立「无创比有创更好」的通用认知，不绑定单一病症。 Build the general case for non-invasive over invasive care — before specific conditions.
体表无任何切口，不留疤痕，不影响外观。 No surface incision or scar — appearance unchanged.
仅镇静镇痛，患者全程清醒可沟通，规避全麻风险。 Sedation and analgesia only — patients stay awake and can communicate, avoiding general-anesthesia risks.
术后 1–3 天恢复正常生活，1 周重返职场，无需长期休养。 Return to daily life in 1–3 days and work in about a week — no long recovery.
保留子宫完整结构与功能，不破坏内分泌与卵巢功能。 Preserves uterine structure and function without disrupting endocrine or ovarian function.
复发、多发病灶可多次治疗，无创伤叠加与盆腔粘连风险。 Recurrent or multiple lesions can be treated again without cumulative trauma or adhesion risk.
术后 3–6 个月即可备孕，远短于传统手术 18–24 个月的等待期。 Conception can often be planned 3–6 months after treatment — much shorter than the 18–24 months typical after surgery.
切口 Incision
传统手术 Surgery
开腹 / 腔镜切口 Open / laparoscopic incision
HIFU 无创 HIFU
体表无切口 No surface incision
麻醉 Anesthesia
传统手术 Surgery
常需全麻 Often general anesthesia
HIFU 无创 HIFU
镇静镇痛，可清醒 Sedation; patient awake
住院 Hospital stay
传统手术 Surgery
通常需住院数日 Often several days
HIFU 无创 HIFU
多数当日可离院 Often same-day discharge
恢复 Recovery
传统手术 Surgery
休养周期较长 Longer recovery
HIFU 无创 HIFU
1–3 天恢复日常 Daily life in 1–3 days
备孕等待 Time to conceive
传统手术 Surgery
约 18–24 个月 About 18–24 months
HIFU 无创 HIFU
约 3–6 个月 About 3–6 months
核心主推两大病种，并简要补充其他适应症。最终需临床医生评估。 Two core conditions, plus brief notes on other indications. Final suitability requires clinical evaluation.
子宫平滑肌细胞异常增生形成的良性肿瘤，与雌激素密切相关。 A benign tumor from abnormal uterine smooth-muscle growth, closely related to estrogen.
约 25% ~25%
育龄期患病率 Reproductive-age prevalence
高达 70% Up to 70%
围绝经初期 Early perimenopause
超千万 10M+
中国患者基数 Patients in China
典型症状 Typical symptoms
子宫内膜侵入子宫肌层生长，被称为「不死的癌症」。 Endometrial tissue grows into the myometrium — sometimes called an “immortal cancer.”
7%–23% 7%–23%
育龄女性发病率 Reproductive-age incidence
可达 40%+ Up to 40%+
有妇科症状女性 Women with gyn. symptoms
重要杀手 Major threat
女性生育力威胁 To fertility
典型症状 Typical symptoms
来自中国临床指南、国际权威机构与全球监管体系的多重认可，为 HIFU 无创治疗提供专业背书。 Endorsement from Chinese clinical guidelines, international authorities, and global regulatory bodies provides professional validation for HIFU non-invasive treatment.
《中国肿瘤整合诊治技术指南（CACA）-HIFU 治疗》2023 年 8 月，在整合医学框架中强调 HIFU 的无创优势与生育保护价值，由 105 位多学科专家联合编写。 Chinese Guidelines for Holistic Integrative Management of Cancer (CACA) — HIFU Treatment, August 2023. Within an integrative medicine framework, this guideline highlights HIFU's non-invasive advantages and fertility-preserving value, authored by 105 multidisciplinary experts.
《子宫肌瘤诊治中国专家共识》2017 年 12 月、《子宫腺肌病诊治中国专家共识》2020 年 6 月，明确将超声引导 HIFU 列为保留生育功能的微无创治疗方案，推荐用于有症状的子宫肌瘤、子宫腺肌症患者。 Chinese Expert Consensus on Uterine Fibroids (December 2017) and Adenomyosis (June 2020). Both explicitly list ultrasound-guided HIFU as a minimally invasive, fertility-preserving option for symptomatic uterine fibroids and adenomyosis.
《聚焦超声消融手术临床应用技术规范专家共识》2020 年，由中国医师协会组织制定，明确超声引导 HIFU 的临床应用规范，将子宫肌瘤、子宫腺肌病列为核心适应证。 Expert Consensus on Clinical Application Standards for Focused Ultrasound Ablation (2020), developed under the Chinese Medical Doctor Association. Defines clinical standards for ultrasound-guided HIFU, with uterine fibroids and adenomyosis as core indications.
《子宫肌瘤诊断和治疗临床指南》2025 年 10 月，将超声引导 HIFU 纳入全球子宫肌瘤治疗指南，作为无创保宫方案正式推荐，明确适用于 FIGO 分型 1–2 型（不适于宫腔镜切除）、3–6 型及 8 型子宫肌瘤，最大直径可达 20cm。认可其为「保留子宫完整性的有效无创治疗选择，尤其适合有生育需求的女性」。 Clinical Guidelines for Diagnosis and Treatment of Uterine Fibroids, October 2025. Ultrasound-guided HIFU is formally recommended as a non-invasive, uterus-preserving option for FIGO types 1–2 (not suitable for hysteroscopic resection), types 3–6, and type 8 fibroids up to 20 cm in maximum diameter. Recognized as an effective non-invasive choice that preserves uterine integrity, especially for women with fertility goals.
《超声引导经皮高强度聚焦超声治疗症状性子宫肌瘤》（IPG657）2019 年 7 月，正式推荐超声引导 HIFU 用于症状性子宫肌瘤治疗，认可其安全性与临床价值，明确适用于要求保留子宫、不能耐受或不愿接受传统手术的患者。 Ultrasound-guided High-Intensity Focused Ultrasound for Symptomatic Uterine Fibroids (IPG657), July 2019. Formally recommends ultrasound-guided HIFU for symptomatic uterine fibroids, affirming its safety and clinical value for patients who wish to preserve the uterus or cannot tolerate or prefer to avoid conventional surgery.
2005 年起批准（持续更新），正式批准超声引导 HIFU 设备用于子宫肌瘤、子宫腺肌病等妇科疾病治疗，纳入医疗器械管理体系，要求严格遵循临床操作规范。 Approved since 2005 (with ongoing updates). Ultrasound-guided HIFU devices are formally approved for gynecologic conditions including uterine fibroids and adenomyosis, regulated under the medical device framework with strict clinical operating standards.
2005 年起批准，认可超声引导 HIFU 设备用于妇科良性肿瘤治疗，允许在欧盟国家临床应用，标志着中国原创技术获得国际主流市场准入认可。 Approved since 2005 for ultrasound-guided HIFU devices in the treatment of benign gynecologic tumors, enabling clinical use across EU member states and marking international market acceptance of this China-origin technology.
想了解更多细节，可以从常见问题或最新临床动态继续。 Continue with FAQs or the latest clinical updates.